803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

BackgroundOver 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last 30 years, highlighting the need for therapy innovation. T cells engineered to express a T cell receptor (TCR) targeting proteins uniquely overe...

Celý popis

Podrobná bibliografie

Vydáno v:	Journal for immunotherapy of cancer Ročník 11; číslo Suppl 1; s. A902
Hlavní autoři:	Anderson, Kristin G, Su, Yapeng, Burnett, Madison G, Bates, Breanna M, Suarez Gutierrez, Magdalia L, Ruskin, Susan L, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BMJ Publishing Group Ltd 01.11.2023 BMJ Publishing Group LTD BMJ Publishing Group
Témata:	Cancer therapies Immunotherapy Lymphocytes Ovarian cancer Regular and Young Investigator Award Abstracts T cell receptors Tumors
ISSN:	2051-1426
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!